Recalls and alerts more than 4 years old are automatically archived. While this information can still be accessed in the database, it has not been altered or updated since it was archived. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats by contacting us.

Update: All Marketed Sibutramine Drugs Voluntarily Withdrawn in Canada

Starting date:
October 13, 2010
Posting date:
October 13, 2010
Type of communication:
Information Update
Subcategory:
Drugs
Source of recall:
Health Canada
Issue:
Product Safety
Audience:
General Public
Identification number:
RA-110003834

Further to Health Canada's October 8, 2010, communication on the voluntary recall by Abbott Laboratories of Meridia® (the brand name for the weight-loss drug sibutramine), Health Canada is updating healthcare practitioners and Canadians with respect to the two generic forms of sibutramine drugs authorized in Canada: Apo-sibutramine and Novo-sibutramine.

Apotex Inc., the manufacturer of Apo-sibutramine, has agreed to voluntarily withdraw this drug from the Canadian market. Teva Canada Ltd., the manufacturer of Novo-sibutramine, has confirmed to Health Canada that it has not marketed this drug in Canada, i.e., Novo-sibutramine is not available for sale on the Canadian market.

As with Meridia®, patients currently taking Apo-sibutramine should contact their healthcare practitioner at their earliest convenience regarding potential alternatives. Pharmacists with questions regarding their current supply of Apo-sibutramine should contact Apotex Inc. directly at 1-877-427-6839 (1-877-4-APOTEX), extension 1601. Patients with questions regarding their current supply should contact their pharmacist.

Media enquiries

Health Canada
613-957-2983

Public enquiries

613-957-2991
1-866-225-0709